Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Nephrology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Kidney Cancer Clinical Trials

A listing of Kidney Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (285) clinical trials

Advanced or Metastatic Renal Cell Carcinoma (RCC)

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.

Phase

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Stage I - Pharmacokinetics (Bioequivalence) Subjects will be randomized to receive CC-486 300 mg orally on each of the two pharmacokinetic (PK) study days based on the dosing sequences they are randomized to: Dosing Sequence 1: 2x150 mg tablets followed by 1x30 mg tablet. Dosing Sequence 2: 1x300 mg tablet ...

Phase

Point of Care 3D Ultrasound for Various Applications: A Pilot Study

Summary Purpose and Objective: The purpose of this study is to test the feasibility of rapid acquisition of point of care 3D ultrasound in obtaining abdominal and/or pelvic images. The study will use a newly developed acquisition method and post-processing technique to create three dimensional image models of the abdomen ...

Phase N/A

A Study of CDX-1140 in Patients With Advanced Solid Tumors

CDX-1140 is a fully human monoclonal antibody that binds to a cell receptor called CD40 found on certain cells to activate the immune system which may promote anti-tumor effects. This study will determine the MTD of CDX-1140 while also evaluating the safety, tolerability and efficacy of CDX-1140. Eligible patients that ...

Phase

Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma

The study will follow the real-life management of patients in clinical practice. Visits will take place according to the study site's clinical practice. Cabozantinib is to be administered as directed by the investigator according to the study site's usual clinical practice and the Cabometyx Summary of Product Characteristics (SmPC).

Phase N/A

Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer

PRIMARY OBJECTIVES: I. To evaluate a novel clinical assay (Myeloid Derived Suppressor Cells [MDSC] Clinical Assay) to detect cancer associated immune cells in the peripheral blood of patients as a means to better detect and monitor malignant renal cell carcinoma in patients. II. Determine mean MDSC level, intra-subject variability, and ...

Phase N/A

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of investigational drugs to learn whether the drugs work in treating a specific disease. "Investigational" means that the intervention is being studied. Nivolumab and ipilimumab are antibodies (a type of human protein) ...

Phase

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

This is a phase 1, open-label, multicenter, dose escalation study that will examine the safety profile of SGN-2FF given orally to patients with advanced solid tumors. The primary goal of the study is to identify the maximum tolerated dose (MTD), or optimal biological dose (OBD) that does not exceed the ...

Phase

A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

Cancer treatments that couple pharmacological activation of tumor antigen presentation with activation and expansion of CD8+ T and natural killer (NK) cells in the tumor environment have the potential to induce an effective anti-tumor immune response in patients. NKTR-262 is a small molecule agonist of toll-like receptors (TLRs) 7/8 designed ...

Phase